Lafayette Investments Inc. Raises Stock Holdings in Novo Nordisk A/S $NVO

Lafayette Investments Inc. boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 44.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 68,845 shares of the company’s stock after buying an additional 21,091 shares during the quarter. Lafayette Investments Inc.’s holdings in Novo Nordisk A/S were worth $3,820,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NVO. True Wealth Design LLC raised its stake in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC raised its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $30,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $37,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.4%

Shares of NYSE NVO opened at $48.91 on Friday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The stock has a market cap of $218.39 billion, a P/E ratio of 14.10 and a beta of 0.67. The firm has a 50-day moving average of $53.71 and a 200 day moving average of $53.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo is planning to roll out Wegovy in vial format (and other device presentations), which could broaden distribution channels, improve dosing flexibility and help meet demand amid intense competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: CEO Mike Doustdar highlighted a potential ~15 million-patient Medicare opportunity once obesity treatments gain coverage — a large TAM that supports long-term revenue upside if access improves. Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
• Positive Sentiment: A study found many Wegovy pill users are new to GLP‑1 therapies, suggesting the product is expanding the market rather than only cannibalizing existing diabetes/weight-loss patients. That supports growth potential if retention and outcomes hold. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Coverage on how Novo is expanding its global healthcare reach highlights strategic initiatives and portfolio breadth, but offers limited immediate impact to near-term earnings. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Coverage comparing Eli Lilly and Novo Nordisk notes intense competition in the weight‑loss market; investors should watch share shifts but the piece is a market-context update rather than firm-specific news. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here’s What Investors Need to Know.
• Neutral Sentiment: Company disclosure of insider trading by board members/executives was published; routine regulatory reporting that bears watching only if it signals large directional bets. Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
• Negative Sentiment: Regulatory pressure is mounting: the FDA flagged a TV ad for the Wegovy pill as misleading and broader reporting highlights potential FDA warnings and lawsuits — these raise reputational, marketing and legal risk that could dent demand or increase costs. Novo’s TV ad for Wegovy pill was misleading, FDA says FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story
• Negative Sentiment: Analysts are turning cautious: Deutsche Bank cut its price target ~16% citing revenue headwinds and risks, and Zacks downgraded Novo to a “strong sell” — analyst actions can pressure sentiment and share price near term. Novo Nordisk target cut by Deutsche Bank despite long-term optimism Zacks Research downgrade

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Citigroup initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.07.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.